B-cell lymphoproliferation in chronic inflammatory rheumatic diseases (Q36956210)

17 August 2017

1 reference

title

B-cell lymphoproliferation in chronic inflammatory rheumatic diseases (English)

1 reference

17 August 2017

0 references

Arne Hansen

1

1 reference

17 August 2017

Peter E Lipsky

series ordinal

2

1 reference

17 August 2017

Thomas Dörner

series ordinal

3

1 reference

17 August 2017

publication date

1 October 2007

1 reference

Nature Clinical Practice Rheumatology

17 August 2017

published in

1 reference

17 August 2017

volume

3

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

561-569

1 reference

TNF Deficiency Fails to Protect BAFF Transgenic Mice against Autoimmunity and Reveals a Predisposition to B Cell Lymphoma

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

The immune system. Second of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Competence and competition: the challenge of becoming a long-lived plasma cell

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

B lymphocytes on the front line of autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

1 reference

7 January 2021

B cells in rheumatoid synovitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

The risk of lymphoma development in autoimmune diseases: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Treatment of rheumatoid arthritis with rituximab: an update and possible indications

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Non-Hodgkin lymphoma: an update

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Autoimmunity and lymphoma: tribulations of B cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in V(H)4-34 expressing single leukemic B cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Risk of lymphoma in patients with RA treated with anti-TNFalpha agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Molecular pathogenesis of Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Cell cycle deregulation in B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

MALT lymphoma: from morphology to molecules

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Lymphoid lesions of the head and neck: a model of lymphocyte homing and lymphomagenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Role of chemokines in the development of secondary and tertiary lymphoid tissues

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Dissemination of a Sjögren's syndrome-associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

A checkpoint for autoreactivity in human IgM+ memory B cell development

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Hepatitis C virus, Sjögren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

1 reference

7 January 2021

B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Preliminary classification of nonmalignant B cell proliferation in Sjögren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

An international cohort study of cancer in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

High relapse rate in patients with MALT lymphoma warrants lifelong follow-up.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Epratuzumab in the therapy of oncological and immunological diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0620

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0620

1 reference

17 August 2017

1 reference